Related Experiment Video
Updated: Sep 22, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
[ANMCO/AICO/AIOM Consensus document: Clinical and management pathways in cardio-oncology]
Luigi Tarantini1, Michele Massimo Gulizia2, Andrea Di Lenarda3
1S.C. Cardiologia, Ospedale San Martino, Azienda ULSS 1, Belluno.
Insights
Cardio-oncology addresses heart damage from cancer treatments, a growing concern with increased cancer survival. This field guides oncologists and cardiologists in managing cancer care while minimizing cardiac risks.
Area of Science:
- Oncology
- Cardiology
- Cardio-oncology
Background:
- Cardiovascular diseases and cancer are leading causes of death in Italy, often coexisting in elderly patients.
- Improved cancer survival leads to increased cardiovascular complications from cardiotoxic cancer therapies.
- This necessitates a collaborative approach between cardiology and oncology.
Purpose of the Study:
- To establish practical recommendations for managing cardiac toxicity in cancer patients.
- To guide the multidisciplinary collaboration between cardiologists and oncologists.
- To optimize cancer treatment while minimizing cardiac risks.
Main Methods:
- Development of a consensus document based on multidisciplinary collaboration.
- Providing practical recommendations for assessment, monitoring, and treatment.
- Focus on protecting heart health throughout oncological disease stages.
Main Results:
- Establishment of cardio-oncology as a clinical discipline.
- Framework for managing and preventing cardiotoxicity.
- Guidelines for integrated cancer and cardiac care.
Conclusions:
- Cardio-oncology is essential for managing cancer patients at risk of cardiac complications.
- Multidisciplinary collaboration is key to balancing cancer treatment efficacy and cardiac safety.
- The consensus document provides a practical guide for clinicians.
Abstract:
In Italy, cardiovascular diseases and cancer are the leading causes of death. Both diseases share the same risk factors and, having the highest incidence and prevalence in the elderly, they often coexist in the same individual. Furthermore, the enhanced survival of cancer patients registered in the last decades and linked to early diagnosis and improvement of care, not infrequently exposes them to the appearance of ominous cardiovascular complications due to the deleterious effects of cancer treatment on the heart and circulatory system. The above considerations have led to the development of a new branch of clinical cardiology based on the principles of multidisciplinary collaboration between cardiologists and oncologists: Cardio-oncology, which aims to find solutions to the prevention, monitoring, diagnosis and treatment of heart damage induced by cancer care in order to pursue, in the individual patient, the best possible care for cancer while minimizing the risk of cardiac toxicity. In this consensus document we provide practical recommendations on how to assess, monitor, treat and supervise the candidate or patient treated with potentially cardiotoxic cancer therapy in order to treat cancer and protect the heart at all stages of the oncological disease.
Related Concept Videos
Standards of Care I
Standards of Care II
Rheumatic Heart Disease III: Medical Management
Coronary Artery Disease V: Interprofessional Care
Cardiomyopathy V: Interprofessional Care
Atherosclerosis III: Management
